Annals of Oncology Advance Access originally published online on June 9, 2005
Annals of Oncology 2005 16(9):1524-1529; doi:10.1093/annonc/mdi271
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
1 Department of Nuclear Medicine, University Hospital Bonn, Bonn 2 Department of Nuclear Medicine, University Hospital Freiburg, Freiburg 3 Department of Diagnostic Radiology, University Hospital Freiburg, Freiburg 4 Department of Hematology & Oncology, University Hospital Freiburg, Freiburg, Germany
* Correspondence to: Dr M. J. Reinhardt, Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Strasse 25, D-53105 Bonn, Germany. Tel: +49-228-287-5186; Fax: +49-228-287-1016; Email: michael.reinhardt{at}ukb.uni-bonn.de
Background: The aim of this study was to evaluate the accuracy of computed tomography (CT) and [18F]fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for prediction of progression-free survival of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) patients after completion of therapy.
Patients and methods: CT and FDG-PET were performed in 40 HD, 17 indolent NHL and 44 aggressive NHL patients (29 women, 72 men; aged 41±14 years) in a median of 2 months after therapy. Progression-free survival was evaluated using the Kaplan–Meier method. Independent prognostic factors were identified by means of Cox proportional hazards model.
Results: CT imaging results were progressive disease (PD) in five, stable disease (SD) in 57, and partial response (PR) or complete remission (CR) in 39 patients. FDG-PET suggested residual lymphoma in 24 patients. Three-year progression-free survival rates after exclusion of five PD patients were: 100% (PET negative; CT: PR or CR), 81% (PET negative; CT: SD), 21% (PET positive; CT: SD) and 0% (PET positive; CT: PR). FDG-PET (P<0.0001) and bulky disease (P <0.05) were identified as independent prognostic variables.
Conclusions: Among lymphoma patients with PR and SD on CT, FDG-PET discriminated those destined to progress into a low risk of 
20% and a high risk for recurrence of 
80%.
Key words: computed tomography, fluorodeoxyglucose, Hodgkin's disease, non-Hodgkin's lymphoma, positron emission tomography
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hutchings and S. F. Barrington PET/CT for Therapy Response Assessment in Lymphoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Han, M. P. Escalon, B. Hsiao, A. Serafini, and I. S. Lossos High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens Ann. Onc., February 1, 2009; 20(2): 309 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein Imaging in staging of malignant lymphoma: a systematic review Blood, January 15, 2008; 111(2): 504 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Lee, A. Saokar, K. J. Dreyer, J. B. Weilburg, J. H. Thrall, and P. F. Hahn Does Radiologist Recommendation for Follow-up with the Same Imaging Modality Contribute Substantially to High-Cost Imaging Volume? Radiology, March 1, 2007; 242(3): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. L. Kasamon, R. J. Jones, and R. L. Wahl Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S. [Abstract] [Full Text] [PDF]
|
|